SGEN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 gruod. 2023 @ 23:00):

Stats
Šios dienos apimtis	19.39M
Vidutinė apimtis	1.63M
Rinkos kapitalizacija	43.15B
EPS	$0 ( 2024-04-25 )
Kita pelno data	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.19
ATR14	$1.424 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Baker Bros. Advisors Lp	Sell	42 977 301	Common Stock
2023-12-14	Baker Bros. Advisors Lp	Sell	8 750	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)
2023-12-14	Baker Bros. Advisors Lp	Sell	9 260	Stock Options (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 44 783 214

Tūris Koreliacija

Ilgas: 0.24 (neutral)

Trumpas: 0.00 (neutral)

Signal:(82.918) Neutral

Seattle Genetics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MLTX	0.927
BLPH	0.927
LGST	0.924
INTA	0.918
SJ	0.917
MOTNU	0.911
MORF	0.907
SVFC	0.907
PESI	0.903
DSEY	0.903

10 Labiausiai neigiamai susiję koreliacijos
ESSA	-0.937
BSRR	-0.937
FNCB	-0.936
SIRI	-0.934
APEI	-0.921
BRKL	-0.92
BLFY	-0.919
ONEM	-0.916
FLIC	-0.913
BCOW	-0.912

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Seattle Genetics Inc Koreliacija - Valiuta/Žaliavos

0.12
( neutral )

0.68
( moderate )

0.61
( weak )

0.33
( neutral )

-0.32
( neutral )

Seattle Genetics Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$1.96B
Bruto pelnas:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2022
Pajamos:	$1.96B
Bruto pelnas:	$1.55B (79.10 %)
EPS:	$-3.30

FY	2021
Pajamos:	$1.57B
Bruto pelnas:	$1.26B (80.21 %)
EPS:	$-3.70

FY	2020
Pajamos:	$2.18B
Bruto pelnas:	$1.96B (89.99 %)
EPS:	$3.51

Financial Reports:

No articles found.

Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.